Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change ...

It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed ...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

Roche has agreed to acquire PathAI, a Boston-based digital pathology firm, for up to $1.05 billion. Roche plans to pay $750 ...

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...